PALO ALTO, Calif.--(BUSINESS WIRE)--Frost & Sullivan is launching a new end-user study on the preferences and drivers of adoption for various Enzyme-linked Immunosorbent Assays (ELISA) and Multiplex Technologies markets. Through more than 150 detailed interviews with a variety of pharmaceutical and biotechnology companies, academic institutions, reference laboratories, clinical laboratories and medical centers, Frost & Sullivan aims to elucidate key drivers and obstacles to adoption and utilization of ELISA and various multiplex technologies.